Clinical trial
Efficacy and Safety of Letrozole vs. Letrozole Plus Zoledronic Acid as Endocrine…
NCT00375752 · Novartis Pharmaceuticals, Industry · Terminated
Key facts
| NCT number | NCT00375752 |
|---|---|
| Title | Efficacy and Safety of Letrozole vs. Letrozole Plus Zoledronic Acid as Endocrine Therapy Before Surgery in Postmenopausal Patients With Breast Cancer |
| Official title | Neoadjuvant Therapy for Postmenopausal Women With ER and/or PgR Positive Breast Cancer. A Randomized Open Phase II Trial Evaluating the Efficacy of a 6 Months Preoperative Treatment With Letrozole (2.5 mg/Day) With or Without Zoledronic Acid (4 mg Every 4 Weeks) |
| Acronym | FEMZONE |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Terminated |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Breast Neoplasms |
| Intervention type | Drug |
| Interventions | Letrozole, Zolendronic Acid |
| Enrollment | 168 |
| Start date | Jun 1, 2006 |
| Primary completion | Dec 16, 2010 |
| Completion | Dec 16, 2010 |
| First posted | Sep 13, 2006 |
| Last update posted | Jun 26, 2017 |
| Countries | Germany |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: